November 2015
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
3
Novocure’s Optune Mya Gets FDA Not Approvable Letter
4
Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL
5
